P. Montcuquet

发表

[Neoadjuvant before surgery treatments: state of the art in prostate cancer].

F. Kleinclauss, M. Paillard, V. Richard, 2014, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

M. Namer, J. Bonneterre, A. Monnier, 2007, British Journal of Cancer.

Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma

X. Pivot, D. Montange, B. Royer, 2014, Cancer Chemotherapy and Pharmacology.

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

M. Namer, J. Bonneterre, A. Monnier, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of vinorelbine in patients with androgen-independent prostate cancer.

M. Piccart, D. Chopin, Y. Humblet, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

M. Namer, C. Jacquillat, D. Khayat, 1990, Cancer.

Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C

F. Guillemin, T. Conroy, C. Rotonda, 2008, Quality of Life Research.

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

F. Fiteni, G. Mouillet, T. Maurina, 2015, Molecular and clinical oncology.

Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.

X. Pivot, F. Fiteni, P. Montcuquet, 2014, Breast.

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis

X. Pivot, F. Fiteni, P. Montcuquet, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.

M. Namer, J. Bonneterre, M. Campone, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma

C. Jacquillat, D. Khayat, P. Fumoleau, 2004, Cancer Chemotherapy and Pharmacology.

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

X. Pivot, P. Montcuquet, L. Mansi, 2013, The oncologist.

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial

F. Kleinclauss, X. Pivot, C. Borg, 2016, Medical Oncology.

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma

M. Namer, P. Fumoleau, P. Kerbrat, 1990, Cancer Chemotherapy and Pharmacology.

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma.

F. Kleinclauss, X. Pivot, M. Paillard, 2014 .

Autologous bone marrow transplantation (ABMT) for acute leukaemia in complete remission: a pilot study of 33 cases

P. Montcuquet, P. Hervé, P. Lutz, 1986, British journal of haematology.

Marrow transplantation from HLA non‐identical family donors for the treatment of leukaemia: a pilot study of 15 patients using additional immunosuppression and T‐cell depletion

P. Montcuquet, P. Hervé, E. Plouvier, 1988, British journal of haematology.

In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

P. Febbo, X. Pivot, S. Butler, 2014, The oncologist.

Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.

X. Pivot, D. Montange, B. Royer, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer

F. Kleinclauss, X. Pivot, Thierry Nguyen, 2012, Clinical Medicine Insights. Oncology.

Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node‐positive, early‐stage, invasive breast carcinoma undergoing breast‐conserving surgery

A. Courdi, A. Monnier, D. Berton‐Rigaud, 2005, Cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

F. Guillemin, T. Conroy, C. Rotonda, 2011, Health and quality of life outcomes.

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.

M. Namer, J. Bonneterre, M. Campone, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.

X. Pivot, A. Llombart-Cussac, J. Sautière, 2011, Breast.

Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.

M. Namer, G. Milano, P. Hurteloup, 1991, Journal of pharmaceutical sciences.

Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results

M. Namer, J. Bonneterre, A. Monnier, 2005 .

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

P. Montcuquet, L. Chaigneau, S. Limat, 2018, Breast Cancer Research and Treatment.

Oncotargets and Therapy Dovepress Clinical Impact of Targeted Therapies in Patients with Metastatic Clear-cell Renal Cell Carcinoma

F. Kleinclauss, X. Pivot, M. Paillard, 2022 .

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

F. Guillemin, T. Conroy, C. Rotonda, 2011, Health and Quality of Life Outcomes.

[Neoadjuvant before surgery treatments: state of the art in prostate cancer].

V. Richard, M.-J. Paillard, G. Mouillet, 2014, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

P. Montcuquet, L. Chaigneau, S. Limat, 2018, Breast Cancer Research and Treatment.

Phase II study of epirubicin in advanced soft tissue sarcoma.

P. Kerbrat, P. Montcuquet, P. Bastit, 1990, Bulletin du cancer.